Michael T Leach
Overview
Explore the profile of Michael T Leach including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
80
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cosimo E, Tarafdar A, Moles M, Holroyd A, Malik N, Catherwood M, et al.
Clin Cancer Res
. 2018 Dec;
25(5):1574-1587.
PMID: 30559170
Purpose: To determine whether inhibition of mTOR kinase-mediated signaling represents a valid therapeutic approach for chronic lymphocytic leukemia (CLL). Experimental Design: Stratification of mTOR activity was carried out in patients...
2.
Cosimo E, McCaig A, Carter-Brzezinski L, Wheadon H, Leach M, Le Ster K, et al.
Clin Cancer Res
. 2013 Mar;
19(9):2393-405.
PMID: 23532892
Purpose: Chronic lymphocytic leukemia (CLL) is currently incurable with standard chemotherapeutic agents, highlighting the need for novel therapies. Overcoming proliferative and cytoprotective signals generated within the microenvironment of lymphoid organs...
3.
McCaig A, Cosimo E, Leach M, Michie A
PLoS One
. 2012 Nov;
7(11):e48929.
PMID: 23133664
Chemokines and their ligands play a critical role in enabling chronic lymphocytic leukaemia (CLL) cells access to protective microenvironmental niches within tissues, ultimately resulting in chemoresistance and relapse: disruption of...
4.
McCaig A, Cosimo E, Leach M, Michie A
Br J Haematol
. 2011 Mar;
153(2):199-211.
PMID: 21352196
As antigenic stimulation of the B cell antigen receptor (BCR) is key to chronic lymphocytic leukaemia (CLL) pathogenesis, targeting dysregulated kinases involved in BCR signalling is an attractive therapeutic approach....